FDA denies bid to stop market entry of generic pain medicine

The FDA ruled that makers of generics can continue producing versions of the painkiller Opana ER's older formulation, saying the new version is not a significant improvement when it comes to stopping drug abuse compared with earlier forms that are not abuse-deterrent. The new version is vulnerable to chewing, grinding, cutting and other manipulation, the FDA said. The ruling is expected to raise concerns with some law-enforcement and community groups fighting drug abuse.

View Full Article in:

New York Times (tiered subscription model), The · Wall Street Journal, The

Published in Briefs: